# US 2010/0166869 A1 · Methods and compositions for treating pulmonary hypertension

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0166869 A1
- Document ID: US20100166869A1
- Status: Published application
- Kind: A1
- Application number: 12/598,406
- Filed: 2008-05-05
- Published: 2010-07-01
- Earliest claimed: 2007-05-03
- Inventors: Neil P. Desai; Patrick Soon-Shiong
- Web page: https://patentgrep.com/patent/US20100166869A1

## CPC

- A61K 9/14: Particulate form, e.g. powders, {Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles (microspheres A61K9/16; microcapsules A61K9/50; nanocapsules, nanoparticles of the matrix type A61K9/51)}
- A61K 31/337: having four-membered rings, e.g. taxol
- A61K 31/436: the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
- A61P 9/12: Antihypertensives
- A61P 9/14: Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention features methods for treating, stabilizing, preventing, and/or delaying pulmonary hypertension by administering nanoparticles that comprise rapamycin or a derivative thereof and/or nanoparticles that comprise a taxane (e.g., paclitaxel) or a derivative thereof. The invention also provides compositions (e.g., unit dosage forms) comprising nanoparticles that comprise a carrier protein and rapamycin or a derivative thereof and/or nanoparticles that comprise a carrier protein and a taxane (e.g. paclitaxel) or a derivative thereof.

## Claims

### Claim 1

A method of treating pulmonary hypertension in an individual, comprising administering to the individual an effective amount of a composition comprising nanoparticles that comprise rapamycin or a derivative thereof and a carrier protein.

### Claim 2 (depends on 1)

The method of claim 1, wherein the pulmonary hypertension is pulmonary arterial hypertension.

### Claim 3 (depends on 2)

The method of claim 2, wherein the pulmonary arterial hypertension is idiopathic pulmonary arterial hypertension.

### Claim at position 4

-5. (canceled)

### Claim 6 (depends on 1)

The method of claim 1, wherein the amount of the rapamycin or derivative thereof in the effective amount of the composition is in the range of about 5 mg to about 500 mg.

### Claim 7 (depends on 6)

The method of claim 6, wherein the amount of the rapamycin or derivative thereof in the effective amount of the composition is about 30 mg to about 300 mg.

### Claim 8 (depends on 1)

The method of claim 1, wherein the rapamycin or derivative thereof is administered parenterally.

### Claim 9 (depends on 8)

The method of claim 8, wherein the rapamycin or derivative thereof is administered intravenously.

### Claim 10 (depends on 1)

The method of claim 1, wherein the rapamycin or derivative thereof is administered by inhalation.

### Claim at position 10

11-13. (canceled)

### Claim 14 (depends on 1)

The method of claim 1, wherein the carrier protein is albumin.

### Claim 15 (depends on 14)

The method of claim 14, wherein the albumin is human serum albumin.

### Claim 16 (depends on 1)

The method of claim 1, wherein the average diameter of the nanoparticles in the composition is no greater than about 200 nm.

### Claim 17

(canceled)

### Claim 18 (depends on 1)

The method of claim 1, wherein the individual is human.

### Claim 19

A unit dosage form for treatment of pulmonary hypertension comprising (a) nanoparticles that comprise a carrier protein and rapamycin or a derivative thereof, wherein the amount of the rapamycin or derivative thereof in the unit dosage form is in the range of about 5 mg to about 500 mg, and (b) a pharmaceutically acceptable carrier.

### Claim at position 17

20-60. (canceled)

### Claim 61

A unit dosage form for treatment of pulmonary hypertension comprising (a) nanoparticles that comprise a carrier protein and a taxane or a derivative thereof, wherein the amount of the taxane or derivative thereof in the unit dosage form is in the range of about 5 mg to about 500 mg, and (b) a pharmaceutically acceptable carrier.

### Claim at position 19

62-84. (canceled)

### Claim 85

A method of treating pulmonary hypertension in an individual, comprising administering to the individual an effective amount of a composition comprising nanoparticles that comprise rapamycin or a derivative thereof and a carrier protein and a composition comprising nanoparticles that comprise a taxane or a derivative thereof and a carrier protein.

### Claim at position 21

86-101. (canceled)
